Skip to main content
SpringerLink
Log in

Planning for the HPV vaccine and its impact on cervical cancer prevention

  • Original Articles
  • Published:
Comprehensive Therapy

Abstract

Genital human papilloma virus (HPV), the most common sexually transmitted disease in the United States, is associated with cervical cancer in women, and penile cancers in men. The infection is asymptomatic until a malignancy develops. Of the more than 90 subtypes, only a small number are associated with malignancies. Vaccines made with recombinant HPV proteins have been shown effective in preventing infection with the more virulent strains of the virus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–527.

    Article  PubMed  Google Scholar 

  2. Cupp MR, Malek RS, Goellner JR, Smith TF, Espy MJ, The detection of human papillomavirus deoxyribonucleic acid in intraepithelial, in situ, verrucous and invasive carcinoma of the penis. J Urol 1995;154:1024–1029.

    Article  PubMed  CAS  Google Scholar 

  3. Frisch M. On the etiology of anal squamous carcinoma. Dan Med Bull 2002;49:194–209.

    PubMed  Google Scholar 

  4. Stubenrauch F, Laimins LA. Human papillomavirus life cycle: active and latent phases. Semin. Cancer Biol 1999;9:379–386.

    Article  PubMed  CAS  Google Scholar 

  5. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423–428.

    Article  PubMed  CAS  Google Scholar 

  6. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157:218–226.

    Article  PubMed  Google Scholar 

  7. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004;4:46–54.

    Article  PubMed  CAS  Google Scholar 

  8. Burk RD. Human papillomavirus and the risk of cervical cancer. Hosp Pract (Off Ed) 1999;34:103–111.

    CAS  Google Scholar 

  9. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3–8.

    Article  PubMed  CAS  Google Scholar 

  10. Rhea WG Jr, Bourgeois BM, Sewell DR. Condyloma acuminata: a fatal disease? Am Surg 1998;64:1082–1087.

    PubMed  Google Scholar 

  11. Bosch FX, Castellsague X, Munoz N, et al. Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. J Natl Cancer Inst 1996;88:1060–1067.

    Article  PubMed  CAS  Google Scholar 

  12. Lajous M, Mueller N, Cruz-Valdez A, et al. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev 2005;14:1710–1716.

    Article  PubMed  CAS  Google Scholar 

  13. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis 2006;6:21–31.

    Article  PubMed  Google Scholar 

  14. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995–3002.

    Article  PubMed  CAS  Google Scholar 

  15. ACOG practice bulletin. Cervical cytology screening. Int J Gynaecol Obstet 2003;83:237–247.

    Google Scholar 

  16. Bernstein SJ, Sanchez-Ramos L, Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol 2001;185:308–317.

    Article  PubMed  CAS  Google Scholar 

  17. White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol 1998;72:959–964.

    PubMed  CAS  Google Scholar 

  18. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271–278.

    Article  PubMed  Google Scholar 

  19. Mao C, Koutsky LA, Ault KA, et al. Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial. Obstet Gynecol 2006;107:18–27.

    PubMed  Google Scholar 

  20. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645–1651.

    Article  PubMed  CAS  Google Scholar 

  21. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004;2:343–347.

    Article  PubMed  CAS  Google Scholar 

  22. Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003;348:489–490.

    Article  PubMed  Google Scholar 

  23. Jastreboff AM, Cymet TC. Role of human papilloma virus in the development of cervical intraepithelial neoplasi and malignancy Postgrad Med J 2002;78:225–228

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johns Hopkins School of Medicine, Baltimore, MD

    Justin Bailey & Tyler Childs Cymet

Authors
  1. Justin Bailey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tyler Childs Cymet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tyler Childs Cymet.

Additional information

The authors have stated that they do not have a significant financial interest or other relationship with any product manufacturer or provider of services discussed in this article. The authors do not discuss the use of off-label products, which includes unlabeled, unapproved, or investigative products or devices.

About this article

Cite this article

Bailey, J., Cymet, T.C. Planning for the HPV vaccine and its impact on cervical cancer prevention. Compr Ther 32, 102–105 (2006). https://doi.org/10.1385/COMP:32:2:102

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/COMP:32:2:102

Keywords

Search

Navigation